Emerging Markets
- Emerging Markets
The PTAB Axes Skin Treatment Patent Under Amgen...
The Patent Trial and Appeal Board (“PTAB”) recently invalidated a University of Massachusetts (“UMass”) patent related to the treatment of the skin disease vitiligo…
- Emerging Markets
Updates in Uruguay – Accession to the PCT and Announcement...
Updates in Uruguay – Accession to the PCT and Announcement of a New GMO Regulatory Framework By: Liz Freeman Rosenzweig Ph.D. and Michael Ward…
- Emerging Markets
Microbes, Biotech Investigations, and Impacts: Midsummer Regulatory Updates from USDA-APHIS...
Microbes, Biotech Investigations, and Impacts: Midsummer Regulatory Updates from USDA-APHIS After overhauling its biotechnology regulations for plants developed using genetic engineering, the United States…
- Emerging Markets
Federal Circuit Wades Into Article III Standing in Patent Cases...
Federal Circuit Wades Into Article III Standing in Patent Cases Once Again By: Ashley E. Sperbeck and Mark D. McBriar Ph.D. Article III standing…
- Emerging Markets
USPTO Seeks Input on Experimental Use Exception to Patent Infringement...
USPTO Seeks Input on Experimental Use Exception to Patent Infringement and Possible Legislative Action By: Jeffrey W. Schmidt Ph.D. and Karen G Potter Ph.D.…
- Emerging Markets
Federal Court Invalidates Dosing Patent Based on Clinical Trials Disclosure...
Federal Court Invalidates Dosing Patent Based on Clinical Trials Disclosure By: Ashley E. Sperbeck and Mark D. McBriar Ph.D. As an essential component of…
- Emerging Markets
Breakthrough Therapy Designation Granted to Bayer’s BAY 2927088 for Non-Small...
Published February 28, 2024 Bayer’s BAY 2927088, a reversible tyrosine kinase inhibitor (TKI) developed in collaboration with the Broad Institute of MIT and Harvard,…